Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 56 Results

Title
Intervention Indication Therapeutic Area Year Actions
Zolbetuximab for previously untreated advanced gastric or gastro-oesophageal junction adenocarcinoma Zolbetuximab (IMAB362) Gastro-oesophageal junction cancer Gastrointestinal Cancer 2022 View  |  Download
Trifluridine and Tipiracil for Metastatic Gastric Cancer – third line and above Lonsurf; TAS-102 (fixed dose combination: Trifluridine; Tipiracil hydrochloride) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2018 View  |  Download
Trastuzumab deruxtecan for HER2-positive gastric or gastroesophageal junction adenocarcinoma – third-line Trastuzumab deruxtecan (DS-8201a; Enhertu) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2021 View  |  Download
Tislelizumab with chemotherapy for previously
untreated advanced oesophageal squamous cell
carcinoma
Tislelizumab (BGB-A317; BGBA-317) Oesophageal squamous cell carcinoma Gastrointestinal Cancer 2022 View  |  Download
Tislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma Chemotherapy , Tislelizumab (BGB-A317; BGBA-317) Gastric cancer , Gastro-oesophageal junction adenocarcinoma Gastrointestinal Cancer 2022 View  |  Download
Tislelizumab for treating unresectable, previously untreated hepatocellular carcinoma Tislelizumab (BGB-A317; BGBA-317) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
siG12D‐LODER in addition to standard chemotherapy for locally advanced pancreatic cancer Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , siG12D-LODER Pancreatic cancer Gastrointestinal Cancer 2018 View  |  Download
Rivoceranib for locally advanced or metastatic gastric or gastro-oesophageal junction cancer - after two or more therapies Rivoceranib (Apatinib; YN968D1) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2020 View  |  Download
Ripretinib for treating advanced gastrointestinal stromal tumours – fourth-line Ripretinib (DCC-2618; Quinlock) Gastrointestinal stromal tumour (GIST) Gastrointestinal Cancer 2020 View  |  Download
Ripretinib for gastrointestinal stromal tumour Ripretinib (DCC-2618; Quinlock) Gastrointestinal stromal tumour (GIST) Gastrointestinal Cancer 2021 View  |  Download
1 2 3 5 6
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications